Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | MGAM | O43451 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | SI | P14410 | 2/20 | 0.51 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.51 |
| ▸ | SNCA | P37840 | 3/20 | 0.48 |
| ▸ | APP | P05067 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL273765 | 0.97 | MEN1 (0.55) | MEN1KMT2ASMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL6705855 | 0.89 | HTR6 (0.47) | MEN1KMT2ASMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL14595569 | 0.77 | MGAM (0.49) | MEN1KMT2ASMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL5645456 | 0.73 | IMPDH2 (0.49) | MEN1KMT2ASMN1; SMN2ALDH1A1MGAM | |
| SCHEMBL27957392 | 0.71 | ALDH1A1 (1.00) | MEN1KMT2ASMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL5622616 | 0.70 | SMN1; SMN2 (0.60) | MEN1KMT2ASMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL2036174 | 0.70 | IMPDH2 (0.51) | MEN1KMT2ASMN1; SMN2ALDH1A1MGAM | |
| SCHEMBL274052 | 0.69 | KMT2A (0.63) | MEN1KMT2ASMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL28628922 | 0.68 | SMN1; SMN2 (0.61) | MEN1KMT2ASMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL27874567 | 0.68 | ALDH1A1 (0.61) | MEN1KMT2ASMN1; SMN2ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524704-B2 | Azepinoindole derivatives as pharmaceutical agents | EXELIXIS, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8466143-B2 | Azepine derivatives as pharmaceutical agents | EXELIXIS, INC. (US) | 2013-06-18 | — | — | US | disclosed |
| US-8133992-B2 | Azepinoindole and pyridoindole derivatives as pharmaceutical agents | EXELIXIS, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20100173824-A1 | Azepinoindole Derivatives As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2010-07-08 | — | — | US | disclosed |
| US-20090326218-A1 | Azepinoindole and Pyridoindole Derivatives as Pharmaceutical Agents | EXELIXIS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-7595311-B2 | Modulating active of receptors; therapy prevention of disease such aas symthrome X, antidiabetic agents, insulin resistance, hypoglycemic agents | EXELIXIS, INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-20090203577-A1 | Azepinoindole Derivatives As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-7485634-B2 | Azepinoindole and pyridoindole derivatives as pharmaceutical agents | EXELIXIS, INC. (US) | 2009-02-03 | — | — | US | disclosed |
| US-20070015746-A1 | Azepine derivaties as pharmaceutical agents | X-CEPTOR THERAPEUTICS INC. (US) | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173824-A1 | Azepinoindole Derivatives As Pharmaceutical Agents | HTR2A, HTR5A, HTR2C | MEN1 2447/4885KMT2A 4330/4885SMN1; SMN2 2899/4885 |
| US-20070015746-A1 | Azepine derivaties as pharmaceutical agents | HTR5A, TACR2, TACR1 | MEN1 2403/4885KMT2A 3460/4885SMN1; SMN2 2388/4885 |
| US-20090326218-A1 | Azepinoindole and Pyridoindole Derivatives as Pharmaceutical Agents | HTR5A, MTNR1A, PTGDR | MEN1 2235/4885KMT2A 4638/4885SMN1; SMN2 2596/4885 |
| US-20090203577-A1 | Azepinoindole Derivatives As Pharmaceutical Agents | NR1H4, NR1I2, GPBAR1 | MEN1 1728/4885KMT2A 4612/4885SMN1; SMN2 4828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.